Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - carcinom, non-small cell lung - antineoplastiska medel - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - carcinom, non-small cell lung - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Europeiska unionen - svenska - EMA (European Medicines Agency)

roche registration gmbh - alectinibhydroklorid - carcinom, non-small cell lung - antineoplastiska medel - alecensa som monoterapi är indicerad för förstahandsbehandling av vuxna patienter med anaplastisk lymfomkinas (alk) -positiv avancerad icke-småcellig lungcancer (nsclc). alecensa som monoterapi är indicerat för behandling av vuxna patienter med alk‑positiv avancerad icke småcellig lungcancer som tidigare har behandlats med crizotinib.

Europeiska unionen - svenska - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - carcinom, non-small cell lung - antineoplastiska medel - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

actavis group ptc ehf. - irinotekanhydrokloridtrihydrat - koncentrat till infusionsvätska, lösning - 20 mg/ml - sorbitol hjälpämne; irinotekanhydrokloridtrihydrat 20 mg aktiv substans - irinotekan

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fresenius kabi ab - irinotekanhydrokloridtrihydrat - koncentrat till infusionsvätska, lösning - 20 mg/ml - sorbitol hjälpämne; irinotekanhydrokloridtrihydrat 20 mg aktiv substans - irinotekan

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - ceritinib - carcinom, non-small cell lung - antineoplastiska medel - zykadia är indicerat för behandling av vuxna patienter med anaplastisk lymfomkinas (alk) positiv, avancerad, icke-småcellad lungcancer (nsclc) som tidigare behandlats med crizotinib.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - irinotekanhydrokloridtrihydrat - koncentrat till infusionsvätska, lösning - 20 mg/ml - irinotekanhydrokloridtrihydrat 20 mg aktiv substans; sorbitol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

janssen-cilag ab - itrakonazol - oral lösning - 10 mg/ml - hydroxipropylbetadex hjälpämne; itrakonazol 10 mg aktiv substans; sorbitol hjälpämne; propylenglykol hjälpämne - itrakonazol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

janssen-cilag ab - itrakonazol - kapsel, hård - 100 mg - itrakonazol 100 mg aktiv substans; sockersfärer hjälpämne - itrakonazol